A high frequency of BRCA mutations in young black women with breast cancer residing in Florida

Cancer

Volumn 121, Issue 23, 2015, Pages 4173-4180

  Pal, Tuya ^a   Bonner, Devon ^a   Cragun, Deborah ^a   Monteiro, Alvaro N A ^a   Phelan, Catherine ^b   Servais, Lily ^a   Kim, Jongphil ^c   Narod, Steven A ^c   Akbari, Mohammad R ^c   Vadaparampil, Susan T ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b DNA Direct Inc   (United States)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

black women; BRCA1; BRCA2; breast cancer; disparities

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER REGISTRY; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC COUNSELING; GENETIC VARIABILITY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SALIVA ANALYSIS; SEQUENCE ANALYSIS; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UNITED STATES; BREAST TUMOR; DNA SEQUENCE; EARLY CANCER DIAGNOSIS; ETHNOLOGY; FLORIDA; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; REGISTER; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FLORIDA; GENETIC COUNSELING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; REGISTRIES; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84948582795     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29645     Document Type: Article

References (30)

1. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http://seer.cancer.gov/. Accessed April 1, 2015.
2. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313:165-173.
3. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295: 2492-2502.
4. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triplenegative tumors in an urban cancer center. Cancer. 2008;113:608-615.
5. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.
6. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006;66:8297-8308.
7. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2014;160:255-266.
8. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304-311.
9. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729-1736.
10. c, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/ testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13:349-355.
11. Pagan JA, Su D, Li L, Armstrong K, Asch DA. Racial and ethnic disparities in awareness of genetic testing for cancer risk. Am J Prev Med. 2009;37:524-530.
12. Newman LA. Breast cancer in African-American women. Oncologist. 2005;10:1-14.
13. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007;298:2869-2876.
14. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998;279:915-921.
15. Palma MD, Domchek SM, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res. 2008;68: 7006-7014.
16. Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, Schoenberger J, Trost J, Wenstrup RJ, Roa BB. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer. 2012; 118:5210-5216.
17. Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S. Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach. Genet Test Mol Biomarkers. 2011;15:69-77.
18. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353-357.
19. Plon SE, Eccles DM, Easton D, et al. IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29: 1282-1291.
20. National Human Genome Research Institute. Breast cancer information core. Available at: http://www.genome.gov/intramural-research/lab-Dransfer/bic. Accessed March 19, 2015.
21. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian, version 2. Available at: http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. Accessed April 10, 2015.
22. Fackenthal JD, Zhang J, Zhang B, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012;131:1114-1123.
23. Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707-714.
24. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222-2233.
25. Zhang J, Fackenthal JD, Zheng Y, et al. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012;134:889-894.
26. Wood ME, Kadlubek P, Pham TH, et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol. 2014;32:824-829.
27. Isakoff SJ, Mayer EL, He L, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33: 1902-1909.
28. Hall MJ, Olopade OI. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006;24:2197-2203.
29. Trottier M, Lunn J, Butler R, et al. Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. Clin Genet. 2015;88:182-186.
30. Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, Royer R, Narod SA, Hurley J. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat. 2011;125:591-596.